Verv secures $3.8M CAD seed round with global leader Randox Laboratories
Summary
Sudbury, July 21, 2022: Verv Technologies Ltd (Verv) is proud to announce a $3.8M CAD seed round from internationally recognized biotechnology and laboratory services leader, Randox Laboratories, UK.Two out of three people want to be able to test their blood at home. Verv is focused on creating the first of its kind consumer-oriented, affordable, high-quality blood chemistry analyser with disposable tests for home use, that will help individuals measure a wide range of analytes (i.e. cholesterol, vitamin levels, hormones). Verv will empower consumers, help them take control of their own health, transform access to blood testing, and improve timely decision-making between consumers and their healthcare providers.Vervs lead investor, Randox Laboratories Ltd. is a globally recognized in-vitro diagnostics leader that develops diagnostic solutions for hospitals, clinical, research and molecular labs, food testing and more. We have a shared vision and belief in Vervs unique, highly differentiated microfluidics approach to creating scalable, high-quality, low-cost blood testing technology for healthcare consumers. We anticipate a great journey ahead, in partnership with Verv.Verv and Randox share a commitment to transform testing on a global scale for the benefit of healthcare consumers.